[Update of BIOBADASER].
As of September 1st, 2008 BIOBADASER has included 9352 patients from 100 centers that provide information on 12,136 treatments with biological therapies. Treatment was discontinued in 4281 (35%) occasions, in the same proportion as a result of an adverse event [1,782 (42%)] and inefficiency or loss of effectiveness [1,816 (42%)]. There have been reported 6814 adverse events, of which the most frequent are infections [2,656 (39%)], followed by disorders related to the administration [1,009 (15%)] and disorders of the skin and subcutaneous tissue [521 (8%)].